Jan 13 2011 |
New Defense Authorization Act Imposes Buy American Act Mandate for Photovoltaics |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 2 2018 |
OIG Report on Topical Compounded Drug Prescribing, Marketing and Billing Practices Signals Heightened Administrative and Enforcement Scrutiny |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 2 2019 |
The Farm Bill’s Impact on Hemp and CBD – and How Some States are Reacting |
Sheppard, Mullin, Richter & Hampton LLP |
May 11 2022 |
Warning! FDA Issues Warning Letters for Products Containing Delta-8 THC |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 27 2022 |
Supreme Court Rules for Physicians in Blow to DOJ |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 16 2014 |
Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions Before Bringing Suit |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 21 2022 |
FDA Issues Final Guidance on Drug and Biological Instructions for Use (IFU) |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 19 2015 |
Go For De Novo: FDA’s Revised Approach to Medical Device Accessories |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 13 2022 |
OIG Limits Pharmaceutical Manufacturers’ Ability to Offer Drug Cost-Sharing Subsidies |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 30 2019 |
CBD Industry Beware: The False Labeling Class Action Has Arrived |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 3 2019 |
Third Circuit Holds that SLUSA Does Not Preclude Class Action Opt-Outs from Pursuing Individual Actions |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 30 2019 |
BREAKING NEWS: USDA Releases Interim Final Hemp Rule |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 29 2023 |
FDA Issues First Untitled Letter of the Year to HCT/P Manufacturer |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 5 2020 |
How FDA is Reacting to the Coronavirus, and 2020 Regulatory Priorities |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 11 2020 |
FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 17 2023 |
United Cannabis Corporation v. Pure Hemp Collective Inc. |
Sheppard, Mullin, Richter & Hampton LLP |
May 11 2020 |
The Expansion of Cardiovascular Procedures in the ASC Setting |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 25 2023 |
Connecticut Follows in the Footsteps of Other Jurisdictions Requiring Registration of Pharmaceutical Representatives |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 13 2020 |
FDA Announces Plans to Resume Domestic On-site Inspections |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 23 2013 |
Federal Trade Commission (FTC) v. Actavis: What Does It Mean for Reverse-Payment Settlements? |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 4 2013 |
European Union (EU) Carbon Trading System Wins Parliament's Support |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 26 2018 |
Ninth Circuit Confirms that Class Action Plaintiffs Must Plausibly Establish Future Intent To Re-Purchase To Maintain Claims for Injunctive Relief |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 28 2021 |
Nota Bene Episode 145: Tuna Sustainability: A Model Bigger than its Niche with ISSF President Susan Jackson [PODCAST] |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 18 2021 |
California Broadens Security and Breach Laws, Includes Genetic Data |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 4 2022 |
Cannabis Legislation Year-in-Review |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 11 2022 |
Federal Cannabis Reform – Is 2022 the Year? |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 4 2022 |
The House Does It Again: MORE Act Ready for Senate Action |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 13 2022 |
States Target Infant Formula Price Gouging |
Sheppard, Mullin, Richter & Hampton LLP |
May 8 2019 |
AAFCO Issues Updated Guidelines Regarding Hemp in Animal Food |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 27 2022 |
PFAS Regulations Could Open Floodgates to Prop 65 Enforcement – Assess & Manage Your Exposure Now |
Sheppard, Mullin, Richter & Hampton LLP |
May 20 2019 |
Location Matters – Manufacturing Insights from FDA’s Annual Report on Drug Quality |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 10 2019 |
FDA Issues Warning Letters to 15 Companies, Consumer Update on CBD Safety |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 15 2020 |
FCPA Landmines Beneath the Surface of the COVID-19 Crisis - May 6 |
Sheppard, Mullin, Richter & Hampton LLP |
May 5 2020 |
IP Protection and the Open COVID Cure Chase |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 13 2023 |
Federal Circuit Evaluates Impact of the Final Written Decision (FWD) in a Parallel Inter-Partes Review (IPR) on District Court’s decision of Invalidity and Infringement |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 18 2024 |
Federal Circuit Affirms Skinny Label Carve Outs |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 29 2024 |
District Court Elucidates the Meaning of “to Induce” Under the Federal Health Care Program Anti-Kickback Statute |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 20 2020 |
California Governor Pulls the Plug on Genetic Information Privacy Act |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 29 2021 |
FDA Announces First Ever Facility Fees for OTC Drug Manufacturers |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 15 2021 |
Breaking Down FDA’s New Remote Monitoring Strategy |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 16 2010 |
Proposition 23's Failure Means Full Speed Ahead on AB 32 |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 9 2018 |
Temporal Proximity Is Not Enough: Third Circuit Nixes FCA/Anti-Kickback Suit For Failure To Link Alleged Scheme to Claims |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 2 2021 |
340B Drug Pricing Discount Program Update: HRSA Now Demands That Drug Manufacturers Provide 340B Discounts To Contract Pharmacies Amid Ongoing Litigation |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 30 2013 |
Food and Drug Administration (“FDA”) Draft Guidance For Industry On Pre-Launch Activities Importation Requests: Dead On Arrival? |
Sheppard, Mullin, Richter & Hampton LLP |
Aug 9 2013 |
Unusual Circumstances: California Supreme Court Upholds Limited Use of Future Conditions Baseline Under California Environmental Quality Act (CEQA) |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 29 2021 |
Impact of NYC’s New Delivery Service Data Sharing Requirement |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 14 2019 |
HIMMS19 Conference – Blockchain Symposium Recap |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 18 2022 |
China Proposed Draft Implementing Rules for Human Genetic Resources Management |
Sheppard, Mullin, Richter & Hampton LLP |
May 19 2022 |
FDA White Paper Signals Shift to Performance-Based Reviews of Mature Quality Systems |
Sheppard, Mullin, Richter & Hampton LLP |
May 1 2019 |
Yes, UCANN! |
Sheppard, Mullin, Richter & Hampton LLP |